III-话题@MedSci

#III#

818篇内容 | 2522人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1916085, encodeId=544519160853b, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=ImmunoGen的抗体 - 药物偶联物Mirvetuximab soravtansine未达到III期卵巢癌研究的主要终点, objectType=article, longId=161544, objectId=4fbf1615443f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4fbf1615443f, replyNumber=0, likeNumber=73, createdTime=2019-12-21, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4fbf1615443f, moduleTitle=ImmunoGen的抗体 - 药物偶联物Mirvetuximab soravtansine未达到III期卵巢癌研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4fbf1615443f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916068, encodeId=54101916068a0, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=Lancet Gastroen Hepatol：慢性丙型肝炎抗病毒新药临床III期试验研究进展, objectType=article, longId=159965, objectId=41ba15996571, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41ba15996571, replyNumber=0, likeNumber=88, createdTime=2019-04-04, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41ba15996571, moduleTitle=Lancet Gastroen Hepatol：慢性丙型肝炎抗病毒新药临床III期试验研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41ba15996571)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916070, encodeId=41c119160e0e4, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=III期临床试验证明恩杂鲁胺与雄激素剥夺疗法（ADT）联合使用明显改善转移性前列腺癌的存活率, objectType=article, longId=160414, objectId=ea1416041497, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea1416041497, replyNumber=0, likeNumber=77, createdTime=2019-12-18, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea1416041497, moduleTitle=III期临床试验证明恩杂鲁胺与雄激素剥夺疗法（ADT）联合使用明显改善转移性前列腺癌的存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea1416041497)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916132, encodeId=a91619161324a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=Ponesimod治疗复发性多发性硬化症的III期研究结果：符合其主要和次要终点, objectType=article, longId=176219, objectId=d8491e621960, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8491e621960, replyNumber=0, likeNumber=63, createdTime=2020-03-05, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8491e621960, moduleTitle=Ponesimod治疗复发性多发性硬化症的III期研究结果：符合其主要和次要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8491e621960)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916124, encodeId=1c051916124c7, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=2019年国际血栓形成和止血学会（ISTH）大会，辉瑞/Sangamo的A型血友病基因疗法显示出持续增加的凝血因子VIII水平, objectType=article, longId=175017, objectId=1c911e501782, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c911e501782, replyNumber=0, likeNumber=65, createdTime=2020-01-22, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c911e501782, moduleTitle=2019年国际血栓形成和止血学会（ISTH）大会，辉瑞/Sangamo的A型血友病基因疗法显示出持续增加的凝血因子VIII水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c911e501782)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916054, encodeId=d7c41916054c6, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=NEJM：Durvalumab可显著延长III期无法切除的非小细胞肺癌患者总生存期, objectType=article, longId=155723, objectId=f948155e2338, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f948155e2338, replyNumber=0, likeNumber=66, createdTime=2019-02-13, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f948155e2338, moduleTitle=NEJM：Durvalumab可显著延长III期无法切除的非小细胞肺癌患者总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f948155e2338)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916128, encodeId=dbf81916128ad, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=2019年国际血栓和止血学会：罗氏艾美赛珠单抗（Emicizumab）在III期研究中再次证明了安全性, objectType=article, longId=175129, objectId=21e61e5129ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21e61e5129ae, replyNumber=0, likeNumber=93, createdTime=2020-02-01, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21e61e5129ae, moduleTitle=2019年国际血栓和止血学会：罗氏艾美赛珠单抗（Emicizumab）在III期研究中再次证明了安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21e61e5129ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916100, encodeId=a76f19161007a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=慢性淋巴细胞白血病：Calquence达到III期临床试验的主要终点, objectType=article, longId=165652, objectId=69a116565258, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69a116565258, replyNumber=0, likeNumber=72, createdTime=2020-03-02, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69a116565258, moduleTitle=慢性淋巴细胞白血病：Calquence达到III期临床试验的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69a116565258)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916113, encodeId=c0261916113ab, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=2019ASCO：阿斯利康的PARP抑制剂Lynparza，在胰腺癌III期临床中表现出色, objectType=article, longId=167610, objectId=0be116e61073, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0be116e61073, replyNumber=0, likeNumber=72, createdTime=2019-10-03, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0be116e61073, moduleTitle=2019ASCO：阿斯利康的PARP抑制剂Lynparza，在胰腺癌III期临床中表现出色, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0be116e61073)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916088, encodeId=236e191608861, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=抗抑郁新药rapastinel遭遇挫折：未达到III期研究的主要终点, objectType=article, longId=161873, objectId=c2ee1618e324, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2ee1618e324, replyNumber=0, likeNumber=68, createdTime=2019-06-02, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2ee1618e324, moduleTitle=抗抑郁新药rapastinel遭遇挫折：未达到III期研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2ee1618e324)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916073, encodeId=5d6919160e3c6, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=默沙东将开展Keytruda治疗前列腺癌的3个III期临床试验, objectType=article, longId=160438, objectId=5b3116043863, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b3116043863, replyNumber=0, likeNumber=80, createdTime=2019-10-26, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b3116043863, moduleTitle=默沙东将开展Keytruda治疗前列腺癌的3个III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b3116043863)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916072, encodeId=af4219160e208, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=NEJM: BAVENCIO（avelumab）联合INLYTA（阿西替尼）在晚期肾细胞癌中的关键性III期数据, objectType=article, longId=160425, objectId=2800160425be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2800160425be, replyNumber=0, likeNumber=101, createdTime=2019-11-04, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2800160425be, moduleTitle=NEJM: BAVENCIO（avelumab）联合INLYTA（阿西替尼）在晚期肾细胞癌中的关键性III期数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2800160425be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916105, encodeId=6548191610509, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=早产儿坏死性小肠结肠炎：IBT和FDA就III期研究的设计达成一致, objectType=article, longId=166544, objectId=2a63166544a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a63166544a6, replyNumber=0, likeNumber=0, createdTime=2020-03-23, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a63166544a6, moduleTitle=早产儿坏死性小肠结肠炎：IBT和FDA就III期研究的设计达成一致, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a63166544a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916093, encodeId=28001916093da, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=和记黄埔医药在中国启动索凡替尼胆道癌IIb/III期临床试验, objectType=article, longId=163509, objectId=ad4a1635092f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad4a1635092f, replyNumber=0, likeNumber=92, createdTime=2019-10-03, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad4a1635092f, moduleTitle=和记黄埔医药在中国启动索凡替尼胆道癌IIb/III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad4a1635092f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916065, encodeId=585a1916065d9, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=BTK抑制剂Imbruvica联合化疗未通过III期转移性胰腺癌试验, objectType=article, longId=158889, objectId=58081588897d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58081588897d, replyNumber=0, likeNumber=70, createdTime=2019-04-09, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58081588897d, moduleTitle=BTK抑制剂Imbruvica联合化疗未通过III期转移性胰腺癌试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58081588897d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916030, encodeId=1e281916030db, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=OPKO公司完成生长激素缺乏患儿（hGH-CTP）的Somatrogon全球III期研究的入组, objectType=article, longId=145945, objectId=022514594548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=022514594548, replyNumber=0, likeNumber=75, createdTime=2018-09-01, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=022514594548, moduleTitle=OPKO公司完成生长激素缺乏患儿（hGH-CTP）的Somatrogon全球III期研究的入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=022514594548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916095, encodeId=ab3d1916095dd, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=2019年美国临床内分泌学家协会（AACE）大会：Teprotumumab治疗甲状腺眼病的III期试验结果, objectType=article, longId=164221, objectId=3dc6164221e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dc6164221e6, replyNumber=0, likeNumber=86, createdTime=2020-03-05, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dc6164221e6, moduleTitle=2019年美国临床内分泌学家协会（AACE）大会：Teprotumumab治疗甲状腺眼病的III期试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3dc6164221e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916037, encodeId=13ff191603e0f, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=III期试验证明IL-23单抗Tildrakizumab在3年内对中度-严重慢性斑块状银屑病患者维持良好疗效和安全性, objectType=article, longId=149073, objectId=52291490e33c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52291490e33c, replyNumber=0, likeNumber=75, createdTime=2019-05-10, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52291490e33c, moduleTitle=III期试验证明IL-23单抗Tildrakizumab在3年内对中度-严重慢性斑块状银屑病患者维持良好疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52291490e33c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916044, encodeId=16911916044b8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=Nature：重大突破！发现环状核酸酶通过降解环状寡腺苷酸让III型CRISPR/Cas系统失活, objectType=article, longId=149984, objectId=3e9814998439, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e9814998439, replyNumber=0, likeNumber=61, createdTime=2019-06-08, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e9814998439, moduleTitle=Nature：重大突破！发现环状核酸酶通过降解环状寡腺苷酸让III型CRISPR/Cas系统失活, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e9814998439)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916058, encodeId=3fe01916058a5, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle="PANDA"登陆巴黎！康柏西普全球多中心III期临床试验欧洲区研究者大会召开, objectType=article, longId=156456, objectId=54b315645636, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54b315645636, replyNumber=0, likeNumber=82, createdTime=2019-01-12, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54b315645636, moduleTitle="PANDA"登陆巴黎！康柏西普全球多中心III期临床试验欧洲区研究者大会召开, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54b315645636)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III

2020-05-29

juliusluan78 (审核中...)

前往app查看评论内容

#III#

ImmunoGen的抗体 - 药物偶联物Mirvetuximab soravtansine未达到III期卵巢癌研究的主要终点

2019-12-21

juliusluan78 (审核中...)

前往app查看评论内容

#III#

Lancet Gastroen Hepatol：慢性丙型肝炎抗病毒新药临床III期试验研究进展

2019-04-04

juliusluan78 (审核中...)

前往app查看评论内容

#III#

III期临床试验证明恩杂鲁胺与雄激素剥夺疗法（ADT）联合使用明显改善转移性前列腺癌的存活率

2019-12-18

juliusluan78 (审核中...)

前往app查看评论内容

#III#

Ponesimod治疗复发性多发性硬化症的III期研究结果：符合其主要和次要终点

2020-03-05

juliusluan78 (审核中...)

前往app查看评论内容

#III#

2019年国际血栓形成和止血学会（ISTH）大会，辉瑞/Sangamo的A型血友病基因疗法显示出持续增加的凝血因子VIII水平

2020-01-22

juliusluan78 (审核中...)

前往app查看评论内容

#III#

NEJM：Durvalumab可显著延长III期无法切除的非小细胞肺癌患者总生存期

2019-02-13

juliusluan78 (审核中...)

前往app查看评论内容

#III#

2019年国际血栓和止血学会：罗氏艾美赛珠单抗（Emicizumab）在III期研究中再次证明了安全性

2020-02-01

juliusluan78 (审核中...)

前往app查看评论内容

#III#

慢性淋巴细胞白血病：Calquence达到III期临床试验的主要终点

2020-03-02

juliusluan78 (审核中...)

前往app查看评论内容

#III#

2019ASCO：阿斯利康的PARP抑制剂Lynparza，在胰腺癌III期临床中表现出色

2019-10-03

juliusluan78 (审核中...)

前往app查看评论内容

#III#

抗抑郁新药rapastinel遭遇挫折：未达到III期研究的主要终点

2019-06-02

juliusluan78 (审核中...)

前往app查看评论内容

#III#

默沙东将开展Keytruda治疗前列腺癌的3个III期临床试验

2019-10-26

juliusluan78 (审核中...)

前往app查看评论内容

#III#

NEJM: BAVENCIO（avelumab）联合INLYTA（阿西替尼）在晚期肾细胞癌中的关键性III期数据

2019-11-04

juliusluan78 (审核中...)

前往app查看评论内容

#III#

早产儿坏死性小肠结肠炎：IBT和FDA就III期研究的设计达成一致

2020-03-23

hb2008ye (审核中...)

前往app查看评论内容

#III#

和记黄埔医药在中国启动索凡替尼胆道癌IIb/III期临床试验

2019-10-03

juliusluan78 (审核中...)

前往app查看评论内容

#III#

BTK抑制剂Imbruvica联合化疗未通过III期转移性胰腺癌试验

2019-04-09

juliusluan78 (审核中...)

前往app查看评论内容

#III#

OPKO公司完成生长激素缺乏患儿（hGH-CTP）的Somatrogon全球III期研究的入组

2018-09-01

juliusluan78 (审核中...)

前往app查看评论内容

#III#

2019年美国临床内分泌学家协会（AACE）大会：Teprotumumab治疗甲状腺眼病的III期试验结果

2020-03-05

juliusluan78 (审核中...)

前往app查看评论内容

#III#

III期试验证明IL-23单抗Tildrakizumab在3年内对中度-严重慢性斑块状银屑病患者维持良好疗效和安全性

2019-05-10

juliusluan78 (审核中...)

前往app查看评论内容

#III#

Nature：重大突破！发现环状核酸酶通过降解环状寡腺苷酸让III型CRISPR/Cas系统失活

2019-06-08

juliusluan78 (审核中...)

前往app查看评论内容

#III#

"PANDA"登陆巴黎！康柏西普全球多中心III期临床试验欧洲区研究者大会召开

2019-01-12

科室
- - 订阅+
  - 更多科室
工具
服务